Data from 34 newly diagnosed AML patients with IDH1 mutations, part of the initial phase I study, was reported separately and showed a CR + CRh rate of 42.4% in the upfront setting, with induction death less than 3%. The gene discussed is IDH1; the disease is acute myeloid leukemia.